5YXW image
Deposition Date 2017-12-07
Release Date 2018-02-21
Last Version Date 2024-11-20
Entry Detail
PDB ID:
5YXW
Keywords:
Title:
Crystal structure of the prefusion form of measles virus fusion protein
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.78 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
I 21 3
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:glycoprotein F2
Gene (Uniprot):F
Chain IDs:A
Chain Length:94
Number of Molecules:1
Biological Source:Measles virus (strain Ichinose-B95a)
Polymer Type:polypeptide(L)
Molecule:glycoprotein F1,measles virus fusion protein
Gene (Uniprot):F
Chain IDs:B
Chain Length:419
Number of Molecules:1
Biological Source:Measles virus (strain Ichinose-B95a), Measles virus
Ligand Molecules
Primary Citation
Structures of the prefusion form of measles virus fusion protein in complex with inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 115 2496 2501 (2018)
PMID: 29463726 DOI: 10.1073/pnas.1718957115

Abstact

Measles virus (MeV), a major cause of childhood morbidity and mortality, is highly immunotropic and one of the most contagious pathogens. MeV may establish, albeit rarely, persistent infection in the central nervous system, causing fatal and intractable neurodegenerative diseases such as subacute sclerosing panencephalitis and measles inclusion body encephalitis. Recent studies have suggested that particular substitutions in the MeV fusion (F) protein are involved in the pathogenesis by destabilizing the F protein and endowing it with hyperfusogenicity. Here we show the crystal structures of the prefusion MeV-F alone and in complex with the small compound AS-48 or a fusion inhibitor peptide. Notably, these independently developed inhibitors bind the same hydrophobic pocket located at the region connecting the head and stalk of MeV-F, where a number of substitutions in MeV isolates from neurodegenerative diseases are also localized. Since these inhibitors could suppress membrane fusion mediated by most of the hyperfusogenic MeV-F mutants, the development of more effective inhibitors based on the structures may be warranted to treat MeV-induced neurodegenerative diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures